STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page / lines No
Title and abstract	1	(*a*) Indicate the study's design with a commonly used term in the title or the abstract	1 / 8-9
		(*b*) Provide in the abstract an informative and balanced summary of what was done and what was found	1-2 / 21-45
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5-6 / 147-178
Objectives	3	State specific objectives, including any prespecified hypotheses	6 / 179-183
Methods			
Study design	4	Present key elements of study design early in the paper	6 / 186-189
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6 / 192-195
Participants	6	(*a*) *Cohort study*—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up *Case-control study*—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls *Cross-sectional study*—Give the eligibility criteria, and the sources and methods of selection of participants	6 / 196-200, 206-208
		(*b*) *Cohort study*—For matched studies, give matching criteria and number of exposed and unexposed *Case-control study*—For matched studies, give matching criteria and the number of controls per case	not applicable
7Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7 / 216-222, 226-228
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7 / 223-225, 8 / 230-258, 8-9 / 260-274
Bias	9	Describe any efforts to address potential sources of bias	—
Study size	10	Explain how the study size was arrived at	—
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	9 / 276-292
Statistical methods	12	(*a*) Describe all statistical methods, including those used to control for confounding	9 / 276-292
		(*b*) Describe any methods used to examine subgroups and interactions	—
		(*c*) Explain how missing data were addressed	—
		(*d*) *Cohort study*—If applicable, explain how loss to follow-up was addressed *Case-control study*—If applicable, explain how matching of cases and controls was addressed *Cross-sectional study*—If applicable, describe analytical methods taking account of sampling strategy	—
		(*e*) Describe any sensitivity analyses	—

Results			
Participants	13 *	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	10 / Table 1, 12 / Table 2, 13 / Table 3, 14 / Table 4, 15 / Table 5
		(b) Give reasons for non-participation at each stage	—
		(c) Consider use of a flow diagram	7 / Figure
Descriptive data	14 *	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	10 / 300-313, 10 / Table 1
		(b) Indicate number of participants with missing data for each variable of interest	not applicable
		(c) *Cohort study*—Summarise follow-up time (eg, average and total amount)	—
Outcome data	15 *	*Cohort study*—Report numbers of outcome events or summary measures over time	—
		Case-control study—Report numbers in each exposure category, or summary measures of exposure	—
		Cross-sectional study—Report numbers of outcome events or summary measures	12 / 352-356, 13 / 365-372, 13-14 / 374-381, 14-15 / 393-400, 15 / 412-415, 13 / Table 3, 14 / Table 4, 15 / Table 5
Main results	16	(*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	11-12 / 323-339, 12 / 353-356, 13 / 365-372, 13-14 / 374-381, 14-15 / 393-400, 15 / 412-415, 16 / 422-425
		(*b*) Report category boundaries when continuous variables were categorized	—
		(*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	—
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	—
Discussion			
Key results	18	Summarise key results with reference to study objectives	17 / 445-448, 454-457, 464-474, 18 / 481-487
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	18 / 490-494, 500-502

Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	18-19 / 505-514
Generalisability	21	Discuss the generalisability (external validity) of the study results	18 / 490-494
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	3 / 70

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.